The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Open accessAbstract
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals. RESULTS: A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group. The median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model). The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group. There were expected adverse events of rash and transient lymphopenia. KLRG1+TIGIT+CD8+ T cells were more common in the teplizumab group than in the placebo group. Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed. CONCLUSIONS: Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Family history of autoimmune diabetes and personal or family history of allergic diseases or other autoimmune diseases increases the risk of autoimmune diabetes compared with the general population (78,79).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, anti-CD3 treatment (teplizumab) has been shown to induce long-term protection (currently up to six years) from T1D in at-risk individuals, but the mechanisms responsible for this long-term protection remain incompletely understood29,30”
From An autoimmune stem-like CD8 T cell population drives type 1 diabetes (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The CD3 monoclonal antibody teplizumab has been shown to delay progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“there is now evidence that the anti-CD3 monoclonal antibody teplizumab delays progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“In one 2019 study with a 2year delay, annualised rates of clinical diabetes were 15% in the teplizumab group and 36% in the placebo group (table 1). 18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Teplizumab delays the onset of clinical type 1 diabetes by a median of 24 months.18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,855
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,000
Integrating Omics into Functional Biomarkers of Type 1 DiabetesPreprint
Long, S. A., & Linsley, P. S. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041602 · Cited by 7
Self-citationThe Teplizumab Saga: The Challenge of Not Getting Lost in Clinical TranslationPreprint
Chatenoud, L., Herold, K. C., Bach, J., & Bluestone, J. A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041600 · Cited by 6
Self-citationAntigen-specific T cell immunotherapy by in vivo mRNA deliveryPreprint
Su, F., Siebart, J. C., Chan, C. S., Wang, M. Y., Yao, X., Trenkle, A. S., Sivakumar, A., Su, M., Harandi, R., Shahrawat, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620946 · Cited by 6
Лаптев, Д. Н., Eremina, I. A., Shubina, J., Янкевич, Т. Э., Sechko, E. A., Goncharova, N. A., & Peterkova, V. A. (2024) · Diabetes Mellitus · doi:10.14341/dm13101 · Cited by 3
What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?
Wilson, M. A. R., & Pozzilli, P. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109132 · Cited by 3
Cavalli, E., Nicoletti, G. R. P., & Nicoletti, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165621 · Cited by 3
Sims, E. K., Russell, W. E., Cuthbertson, D. D., Skyler, J. S., Jacobsen, L. M., Ismail, H. M., REDONDO, M. J., Nathan, B. M., Carr, A. L. J., Taylor, P. N., et al. (2025) · Diabetes · doi:10.2337/db25-0310 · Cited by 4
Self-citationTwig, G., Simchoni, M., Dym, I., Vinograd, A., Bendor, C. D., Bardugo, A., Tsur, A. M., Zucker, I., Lutski, M., Derazne, E., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1423 · Cited by 3
Wouters, A., Lemaître, P., Degroote, L., Viaene, M., Packbier, M., Geukens, N., Mathieu, C., & Gysemans, C. A. (2025) · Diabetologia · doi:10.1007/s00125-025-06604-2 · Cited by 3
Majstorovic, M., McGorm, K. J., Wentworth, J. M., Couper, J., & Oxlad, M. (2025) · Diabetic Medicine · doi:10.1111/dme.70178 · Cited by 3
Bandura, M., Piotrowska, M., Hennig, M., Gliwiński, M., Wołoszyn‐Durkiewicz, A., Schoenhoff, J., Dybowska, M., Alska, A., Gutknecht, P. G., Trzeciak, B. G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70330 · Cited by 3
Fisher, M. S., Philippova, J., Васильевич, К. В., & Sennikov, S. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311563 · Cited by 4
Piemonti, L., Bolla, A. M., Caretto, A., Melzi, R., Mercalli, A., Sordi, V., Monti, P., Magistretti, P., Lampasona, V., Marzinotto, I., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103685 · Cited by 3
Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression
Triolo, T. M., Sosenko, J. M., Cuthbertson, D. D., Oram, R. A., Parikh, H. M., Steck, A. K., Sims, E. K., Jacobsen, L. M., Nathan, B. M., Templeman, E. L., et al. (2025) · Diabetes · doi:10.2337/db25-0711 · Cited by 4
Tailoring interventions to close gaps in diabetes mellitus care
Diaz-Thomas, A., Cabrera, S. M., Pereira, R. I., & Iyer, P. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01217-6 · Cited by 4
Longitudinal monitoring of type 1 diabetes progression to disease onset
King, J. L., Roy, J., Urie, R. R., Bealer, E. J., Crumley, K. M., Rad, L. M., Soleimanpour, S. A., & Shea, L. D. (2026) · Science Advances · doi:10.1126/sciadv.adw8946 · Cited by 4
Black, S., Tully, A. S., Davis, E. A., Roberts, A., Binkowski, S., Cromb, L., Taplin, C. E., Mellor, B.-R., Bebbington, K. R., & Haynes, A. (2026) · Diabetologia · doi:10.1007/s00125-026-06668-8 · Cited by 3
Ziegler, A., Rewers, M. J., Achenbach, P., Bell, K. J., Bonifacio, E., DiMeglio, L. A., Dutta, S., Larsson, H. E., Frohnert, B. I., Griffin, K., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06841-z · Cited by 4
Self-citationPham, V. T., Ciccaglione, M., Ramirez, D. G., & Benninger, R. K. P. (2020) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2022.03.013 · Cited by 3
Hypothesis: Induction of Autoimmunity in Type 1 Diabetes—A Lipid Focus
Corkey, B. E., Kilpatrick, L. E., & Evans‐Molina, C. (2022) · Diabetes · doi:10.2337/db22-0240 · Cited by 3
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 3
Type 1 diabetes – What’s new in prevention and therapeutic strategies?
Pilśniak, A., & Otto-Buczkowska, E. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.132028 · Cited by 3
Kay, J., Nikolov, N. P., & Weisman, M. H. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42864 · Cited by 3
D’Addio, F., Nasr, M. B., Lunati, M. E., & Fiorina, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00075-8 · Cited by 3
Casas, R., Tompa, A., Åkesson, K., Teixeira, P. F., Lindqvist, A., & Ludvigsson, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010374 · Cited by 3
Peralta, F. G., Pinés-Corrales, P. J., Santos, E., Cuesta, M., Albarrán, O. G., Azriel, S., Castaño, L. A., Mathieu, C., & on behalf of the AGORA Diabetes Collaborative Group (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020418 · Cited by 4
Jiang, Y., Xu, Z., Wu, Y., Li, X., Ling, J., Chen, Y., Zhu, Z., Yang, P., Liu, X., Zhang, D., et al. (2025) · Obesity Reviews · doi:10.1111/obr.13888 · Cited by 3
Lacorcia, M., Bhattacharjee, P., Foster, A., Hardy, M. Y., Tye–Din, J. A., Karas, J. A., Wentworth, J. M., Cameron, F. J., & Mannering, S. I. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt2124 · Cited by 3
Type 1 Diabetes Polygenic Scores Improve Diagnostic Accuracy in Pediatric Diabetes Care
Kreienkamp, R. J., Deutsch, A. J., Huerta‐Chagoya, A., Borglund, E. M., Florez, J. C., Flannick, J. A., & Udler, M. S. (2025) · Hormone Research in Paediatrics · doi:10.1159/000546445 · Cited by 4
Choe, J., Belmonte, P. J., Crotts, S. B., Nguyen, T., Friedman, D. J., Zastrow, A. L., Rajcula, M. J., Hammer, B., Wilhelm, C., Shapiro, M. J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181207 · Cited by 3
IBD Prediction Is Possible, but How Far Are We from Implementing It?
Turpin, W., Kalili, H., Halfvarson, J., & Croitoru, K. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf197 · Cited by 3
Altered B cell metabolic pathways characterize type 1 diabetes progression
Conway, H., Bernard, J., Ramos, R., Zahran, S., Perez, D., Swar-Eldahab, M., Piganelli, J. D., Evans‐Molina, C., & Felton, J. L. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf330 · Cited by 4
Die Behandlung des Diabetes mellitus: Mythen und Evidenz
Göke, B. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03124-9 · Cited by 4
A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy
Crespo, J., Koh, Y. T., Hu, N., Moore, P. A., Bonvini, E., Glasebrook, A. L., Martin, A. P., & Benschop, R. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245917 · Cited by 4
Next-gen therapeutics to spare and expand beta-cell mass
Bolla, A. M., Usuelli, V., Nasr, M. B., Frigerio, S., Loretelli, C., D’Addio, F., & Fiorina, P. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.001 · Cited by 3
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials
Min, T., & Bain, S. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2188191 · Cited by 4
Huang, C.-C., Sung, H.-H., Li, H.-C., Miaw, S., Kung, J. T., Chou, M., & Wu‐Hsieh, B. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1201853 · Cited by 3
Prevention of Type 1 Diabetes: Current Perspective
Pande, A. K., Dutta, D., & Singla, R. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_78_23 · Cited by 6
Lai, X., Luo, J., Luo, Y., Zheng, Y., Yang, H. M., & Zou, F. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107433 · Cited by 3
Aung, N. L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0099 · Cited by 3
Alterations of the pancreas in type 1 diabetes – from prior to diagnosis to long-standing disease
Missima, N. G., Hill, H., Aioanei, C. S., Liss, P., & Espes, D. (2025) · Endocrine · doi:10.1007/s12020-025-04338-0 · Cited by 4
Preventing type 1 diabetes development and preserving beta-cell function
Mastrandrea, L. D., & Quattrin, T. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000746 · Cited by 3
SOCIO–ECONOMIC ASPECT OF TYPE 2 DIABETES IMPACT ON THE LIVES OF PATIENTS
Рогач, І. М., Reho, O. Y., Havrosh, N. V., & Kachur, M. M. (2021) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2021-1-159-355-358 · Cited by 3
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., Rosenblum, N. D., Rosenblum, N. D., Cefalu, W. T., et al. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.09.126 · Cited by 3
Winter, W. E., Pelletier, J. P. R., & Harris, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815499-1.00034-x · Cited by 3
Review on Monoclonal Antibodies (mAbs) as a Therapeutic Approach for Type 1 Diabetes
Agarwal, G., & Patel, M. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230831153249 · Cited by 4
Klatzmann, D. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216267 · Cited by 3
A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerancePreprint
Anderson, M. S., Warshauer, J. T., Belk, J. A., Chan, A. Y. K., Wang, J., Gupta, A. R., Acenas, D. D., II, Shi, Q., Peng, Y., Phipps, J. D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-257641/v1 · Cited by 3
Secreted cytokines provide local immune tolerance for human stem cell-derived isletsPreprint
Gerace, D., Zhou, Q., Kenty, J. H.-R., Sintov, E., Wang, X., Boulanger, K. R., Li, H., & Melton, D. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.09.487072 · Cited by 3
Generating Biomedical Knowledge Graphs from Knowledge Bases, Registries, and Multiomic DataPreprint
Qin, G., Narsinh, K., Wei, Q., Roach, J. C., Joshi, A., Goetz, S. L., Moxon, S. A. T., Brush, M., Xu, C., Yao, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.14.623648 · Cited by 3
Parajuli, A., Bendes, A., Byvald, F., Stone, V. M., Ringqvist, E. E., Butrym, M., Angelis, E., Kipper, S., Bauer, S., Roxhed, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.19.624292 · Cited by 3
Steenbuck, N., Damond, N., Engler, S., Kusmartseva, I., Posgai, A. L., Drotar, D. M., Williams, M. D., de Souza, N., Brusko, T. M., Brusko, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.05.641526 · Cited by 3
Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi, A. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.126360 · Cited by 2
Elevated Serum IgA at Onset of Type 1 Diabetes in Children
Thakkar, A., Huang, X., Wang, J. Z., Hwu, K., Chinn, I. K., Minard, C. G., Hajjar, J., & REDONDO, M. J. (2024) · Pediatric Diabetes · doi:10.1155/2024/7284088 · Cited by 2
King, J. L., Urie, R. R., Morris, A. H., Rad, L. M., Bealer, E. J., Kasputis, T., & Shea, L. D. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28824 · Cited by 3
Immunosuppressive agents in diabetes treatment: Hope or despair?
Li, L., Yang, X., Ren, J.-S., Huang, M., & Zhao, Q. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.100590 · Cited by 2
Quinn, L. M., Boiko, O. V., Elliott, J., Randell, M., Litchfield, I. J., Boardman, F., Dias, R. P., Greenfield, S., & Narendran, P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16639 · Cited by 4
Diabetes mellitus and psoriatic arthritis
Паневин, Т. С., Neupokoeva, A. A., & Korotaeva, T. V. (2025) · Diabetes Mellitus · doi:10.14341/dm13296 · Cited by 2
Perspectives on prevention of type 1 diabetes and heterogeneities
Stene, L. C. (2025) · Diabetologia · doi:10.1007/s00125-025-06512-5 · Cited by 2
Raised levels of Interleukin‐8 and myeloperoxidase in patients with recent onset type 1 diabetes
Alhamar, G., Fallucca, S., Richardson, S. J., Torabi, F., Christie, M. R., Vadakekolathu, J. N., Boocock, D. J., Pieralice, S., Manfrini, S., & Pozzilli, P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70048 · Cited by 2
Tong, L., Tu, Y., Huang, S., & Zheng, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677177 · Cited by 2
Advances and future perspectives in the treatment and prognosis of type 1 diabetes mellitus
Fu, Y., Zeng, J., & He, Q. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1651061 · Cited by 2
Mathieu, C., Quinlan, M., Wagner, K., Kompa, J., Hartmann, N., Hughes, M., Hinder, M., O’Donnell, C. J., & Goldfine, A. B. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251396115 · Cited by 2
Towards insulin independence in type 1 diabetes: Prospects for prevention and cure
Sydney, G. I., Perdigoto, A. L., & Herold, K. C. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004813 · Cited by 2
Self-citationImmune cell-based transcriptomic Mendelian randomization and colocalization study on type 1 diabetes
Sklar, J., Stacey, D., Nickel, G., Butterworth, A. S., Allara, E., & Gaziano, L. (2025) · BMC Medicine · doi:10.1186/s12916-025-04527-8 · Cited by 4
Ansari, M. M., Min, Y., Ko, E., Kwon, D., Khan, R., & Son, Y. (2026) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500233 · Cited by 2
Innovative Therapeutic Paradigms in Diabetes Mellitus: Current Progress and Future Directions
Sattar, A. (2026) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v9i1.1325 · Cited by 2
Keisala, E., Kauppala, T., Vanhamäki, S., Haapakoski, J., Laatikainen, T., & Metso, S. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109312 · Cited by 2
Type I Interferons as Contextual Regulators of B-Cell Tolerance in Type 1 Diabetes
Tedla, M. G., & Felton, J. L. (2026) · Biomolecules · doi:10.3390/biom16040563 · Cited by 2
Chobot, A. P., Bossowski, A. T., Jarosz-Chobot, P. A., Myśliwiec, M., Szadkowska, A., Szypowska, A., & Walczak, M. (2026) · Hormone Research in Paediatrics · doi:10.1159/000551858 · Cited by 2
Perspectives on Sustainability in the Pharmaceutical Industry
Rose, H. B., Sue, H. S., Eastgate, M. D., Kopach, M. E., Yazdanpanah, N., Diwan, M., & Bommarius, B. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00454 · Cited by 2
Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality?
Solitano, V., Jairath, V., Magro, F., Armuzzi, A., Peyrin‐Biroulet, L., & Danese, S. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00085-3 · Cited by 3
Novel Treatments and the Future of DKD: What Is on the Horizon?
Wu, H., & Batuman, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_28 · Cited by 2
How a pioneering diabetes drug offers hope for preventing autoimmune disorders
Dolgin, E. (2023) · Nature · doi:10.1038/d41586-023-00400-x · Cited by 2
Chen, C., Kooi, A. V., Cavedon, A., Cai, X., Hoggatt, J., Martini, P. G. V., & Miao, C. H. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102043 · Cited by 3
Santana, E., & Rosenthal, K. S. (2023) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001317 · Cited by 2
Desouter, A. K., Keymeulen, B., Demeester, S., de Velde, U. V., Pauw, P. E. M. D., Dalem, A. V., Lapauw, B., Block, C. E. M. D., Gillard, P., PIPELEERS, D. G., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110974 · Cited by 3
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
Su, Y.-T., Chou, Y.-H., Chiu, C.-F., Huang, Y.-C., & Lo, F. (2024) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2023.09.010 · Cited by 2
Is Epstein Barr virus latency protective against type 1 diabetes?
Żołędziewska, M. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111314 · Cited by 2
Diabetes treatment by conversion of gut epithelial cells to insulin‐producing cells
Accili, D., Talchai, S. C., Bouchi, R., Lee, A. Y., Du, W. J., Kitamoto, T., McKimpson, W. M., Belvedere, S., & Lin, H. V. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14175 · Cited by 2
Continuous and Intermittent Glucose Monitoring in 2023
Dovč, K., Bode, B. W., & Battelino, T. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2502 · Cited by 3
Ota, T., Goto, R., Harada, T., Forgioni, A., Kanazawa, R., Ganchiku, Y., Kawamura, N., Watanabe, M., Fukai, M., Shimamura, T., et al. (2024) · ImmunoHorizons · doi:10.4049/immunohorizons.2300117 · Cited by 2
Screening per diabete mellito tipo 1 e celiachia: intenzioni, pregi e difetti
Tornese, G., & Greco, L. (2024) · Medico e Bambino · doi:10.53126/meb43243 · Cited by 2
Gomes, M. B., dos Santos, G. C., Azulay, R. S. D. S., Santos, D. C., Da, S., Carvalho, P. R. V. B., Negrato, C. A., & Pôrto, L. C. (2024) · HLA · doi:10.1111/tan.15574 · Cited by 4
Al-Gadi, I., Albalawi, A. D., & Khalifah, R. A. A. (2024) · Pediatric Diabetes · doi:10.1155/2024/1286029 · Cited by 2
Rabaan, A. A., Alfaresi, M. S., AlRasheed, H. A., Kaabi, N. A. M. A., Abduljabbar, W. A., Fares, M. A. A., Al‐Subaie, M. F., & Alissa, M. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400895 · Cited by 2
Diabetes in Children and Adolescents
Šumnı́k, Z., & Průhová, Š. (2024) · Endocrinology · doi:10.1007/978-3-030-23709-7_10 · Cited by 2
Diagnostik, Therapie und Verlaufskontrolle des Typ-1-Diabetes mellitus im Kindes- und Jugendalter
Holder, M., Ziegler, R., Kamrath, C., Lange, K., & Kummer, S. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2374-0813 · Cited by 2
Reversing Diabetes With Your Own Cells: Closer to the Dream
Genosar, R., Coman, M., & Herold, K. C. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae851 · Cited by 2
Self-citationSosenko, J. M., Cuthbertson, D. D., Jacobsen, L. M., REDONDO, M. J., Sims, E. K., Ismail, H. M., Herold, K. C., Skyler, J. S., Nathan, B. M., & Groups, D.-1. A. T. S. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0422 · Cited by 2
Self-citationWang, C., Wang, Y., Zheng, W., Wu, J., Shen, Y., Ji, J., & Du, P. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.09.009 · Cited by 2
Immune Intervention in Type 1 Diabetes
Nambam, B., Bratina, N., & Schatz, D. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.2511 · Cited by 2
Self-citationBogdani, M., Faxius, L., Fex, M., Ramelius, A., Wernersson, A., Mordes, J. P., Blankenhorn, E. P., & Lernmark, Å. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.629242 · Cited by 2
Clark, M., Kroger, C. J., Qi, K., Zhang, R., Statum, K., Milner, J. J., Martin, A. J., Wang, B., & Tisch, R. (2021) · JCI Insight · doi:10.1172/jci.insight.149130 · Cited by 2
SCFAs in T1D: A microbiota-targeted approach for immune tolerance
Mariño, E. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100355 · Cited by 2
Wesley, J. D., Pagni, P. P., Bergholdt, R., Kreiner, F. F., & von Herrath, M. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000742 · Cited by 2
Bini, J., Carson, R. E., & Cline, G. W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2807-2_4 · Cited by 2
Esquivel, D., Mishra, R., & Srivastava, A. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230411111320 · Cited by 2
Stathi, D., Hussain, S., Crawley, D., & Karalliedde, J. J. (2023) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0389 · Cited by 2
Metadata
- Authors
- Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., Marks, J. B., Moore, W., Moran, A., Rodriguez, H., Russell, W. E., Schatz, D., Skyler, J. S., Tsalikian, E., Wherrett, D. K., Ziegler, A.-G., & Greenbaum, C. J.
- Affiliations
- University of Miami (US)
- Children's Mercy Hospital (US)
- University of Minnesota (US)
- University of Iowa (US)
- ORCID
- Herold, Kevan C.
- Bundy, Brian N.
- Long, S. Alice
- Bluestone, Jeffrey A.
- DiMeglio, Linda A.
- Dufort, Matthew J.
- Gitelman, Stephen E.
- Gottlieb, Peter A.
- Krischer, Jeffrey P.
- Linsley, Peter S.
- Marks, Jennifer B.
- Moran, Antoinette
- Rodriguez, Henry
- Russell, William E.
- Schatz, Desmond
- Skyler, Jay S.
- Tsalikian, Eva
- Wherrett, Diane K.
- Ziegler, Anette-Gabriele
- Greenbaum, Carla J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-15
- Volume
- 381
- Issue
- 7
- Pages
- 603-613
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6776880
- OpenAlex
- W2948104235
- Semantic Scholar
- a5198a4024a6f0aecc74d1501dd9fd2892f98796
- Cited by
- 1,189
- References
- 48
- Citations by year
- 2026: 186 · 2025: 209 · 2024: 211 · 2023: 181 · 2022: 123 · 2021: 148 · 2020: 98 · 2019: 32
- FWCI
- 60.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085509, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK107013, U01 DK107014, UC4 DK085466, UC4 DK097835, UC4 DK106993)
- JDRF
- American Diabetes Association
- The Immune Tolerance Network (UM1 AI09565)
- National Center for Research Resources, through Clinical Translational Science Awards (UL1TR000064, UL1TR000114, UL1TR000142, UL1TR000445, UL1TR001082, UL1TR001857, UL1TR001872, UL1TR002366, UL1TR002529, UL1TR002537)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- teplizumab, anti-CD3 monoclonal antibody, type 1 diabetes prevention, high-risk relatives, TIGIT, HLA-DR3, HLA-DR4, zinc transporter 8 antibodies, islet autoimmunity, lymphopenia
- MeSH terms
- Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Exanthema, Female, Glucose Tolerance Test, Humans, Lymphopenia, Male, Middle Aged, T-Lymphocytes, HLA-DR3 Antigen, HLA-DR4 Antigen, Proportional Hazards Models, CD3 Complex, Disease Progression, Lymphocyte Count, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
